Industry-veteran Elisa Cascade Joins Science 37 as Chief Product Officer; Chris Ceppi appointed Chief Technology Officer
October 13 2021 - 7:55AM
Science 37, the Operating System for today’s more agile clinical
trials, announced Elisa Cascade has joined Science 37 and its
senior executive team as Chief Product Officer. Science 37 veteran
Chris Ceppi has been appointed to serve as Chief Technology
Officer.
Ms. Cascade brings more than 30 years of experience in clinical
trial technology, direct-to-patient operations and healthcare
strategy, joining Science 37 most recently from ERT where she
served as Executive Vice President and Product Line Executive for
electronic Clinical Outcomes Assessments (eCOA). Prior to ERT, Ms.
Cascade held the role as Chief Product Officer of DrugDev, an IQVIA
Company, and Vice President of the Digital Patient Unit at
Quintiles. With her extensive clinical trial and technology
experience, Ms. Cascade adds additional strategic prowess and
decades of execution expertise to Science 37’s Operating System and
its ability to accelerate study timelines, minimize patient burden
and enroll a more representative patient population.
Science 37 veteran and architect of the Science 37 technology
platform, Mr. Ceppi serves in a new leadership role as Chief
Technology Officer to provide greater focus on platform and data
infrastructure as a service and competitive advantage.
“We’re pleased to have Elisa join Science 37. With her vast
industry experience, she brings tremendous acumen and clinical
trial technology expertise that will help fuel our mission of
enabling universal access to clinical research,” said David Coman,
Chief Executive Officer of Science 37. “Elisa has been instrumental
in using technology to help transform the industry and enable a
better way to serve all clinical trial stakeholders. She will be a
great complement to Chris, as CTO, where his technology leadership
will be focused on delivering innovation that ensures our Operating
System continues to thrive with a solid foundation of
technology.”
“As the pioneer of the decentralized
clinical trial model, Science 37 has been leading the way to a more
patient-centric future for research and driving toward a more
adaptable, agile clinical trial,” said Elisa Cascade, Chief Product
Officer of Science 37. “It’s a very transformative moment for the
company and the industry and I’m looking forward to working
together to accelerate timelines and make research more
representative by enabling access for patients and providers,
anywhere.”
About Science
37: Science 37, Inc.’s missions it to enable
universal access to clinical research—making it easier for patients
and providers to participate from anywhere and helping to
accelerate the development of treatments that impact patient lives.
As a pioneer of decentralized clinical trials, the Science 37
Clinical Trial Operating System (OS) supports today’s more agile
clinical research designs with its full stack, end-to-end
technology platform and specialized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators and connected devices. Configurable to enable any
study type, the Science 37 OS enables up to 15x faster enrollment,
28% better retention and 3x more diverse patient population with
industry-leading workflow orchestration, evidence generation and
data harmonization. For more information, visit
https://www.science37.com.
MEDIA INQUIRIES:Margie KoomanScience 37Phone:
(984) 377-3737Email: pr@science37.com
INVESTOR RELATIONS:Caroline PaulGilmartin
Groupinvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jul 2023 to Jul 2024